Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Freeze Thaws: US FDA Allowed To Hire Staff For Cures, User Fee Activity

Executive Summary

White House allowed agency to hire some new employees, but lawmakers remain concerned about federal hiring freeze's effect on FDA.

You may also be interested in...



US FDA Expands 'Cures' Hiring Authority To Fill Variety Of Open Positions

Originally used for leadership positions, the alternative pay scale and a revamped hiring pilot are now shortening the time for FDA to onboard even technical staff, but the Office of New Drugs remains 'very understaffed.'

US FDA's Hiring: First Phase Of Cures Implementation Will Focus On Senior Staff

Workforce report to Congress, mandated by 21st Century Cures Act, details FDA's plans for implementing its new authorities provided by the law. 

US FDA Hiring For Senior Staff Vacancies Boosted By Cures Act, Pilot Program – Gottlieb

Recent departures are 'business as usual' at the agency, Commissioner says. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel